title: mTOR signaling pathway and mTOR inhibitors in cancer therapy.
abstract: Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great responses obtained in tumors addicted to specific mutations or overactivation of key members of the mTOR pathway (HiF1α in RCC, cyclin D1 in MCL, or TSC in SEGA), mTOR inhibitors as single agents have modest activity. Dual PI3K/mTOR kinase inhibitors have been developed with the idea of overcoming resistance to the mTOR inhibition through preventing the activation of PI3K/Akt as a result of release negative feedback loops.
authors.affiliation: Department of Medicine, NYU Cancer Institute, New York University School of Medicine, 160 East 34th Street, 8th Floor, New York, NY 10016, USA.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Gomez-Pinillos
authors.forename: Anna C
authors.initials: AC
authors.lastname: Ferrari
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases